Models in Translational Oncology: A Public Resource Database for Preclinical Cancer Research.

The devastating diseases of human cancer are mimicked in basic and translational cancer research by a steadily increasing number of tumor models, a situation requiring a platform with standardized reports to share model data. Models in Translational Oncology (MiTO) database was developed as a unique Web platform aiming for a comprehensive overview of preclinical models covering genetically engineered organisms, models of transplantation, chemical/physical induction, or spontaneous development, reviewed here. MiTO serves data entry for metastasis profiles and interventions. Moreover, cell lines and animal lines including tool strains can be recorded. Hyperlinks for connection with other databases and file uploads as supplementary information are supported. Several communication tools are offered to facilitate exchange of information. Notably, intellectual property can be protected prior to publication by inventor-defined accessibility of any given model. Data recall is via a highly configurable keyword search. Genome editing is expected to result in changes of the spectrum of model organisms, a reason to open MiTO for species-independent data. Registered users may deposit own model fact sheets (FS). MiTO experts check them for plausibility. Independently, manually curated FS are provided to principle investigators for revision and publication. Importantly, noneditable versions of reviewed FS can be cited in peer-reviewed journals. Cancer Res; 77(10); 2557-63. ©2017 AACR.

[1]  A. Jimeno,et al.  Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. , 2016, Cancer research.

[2]  I. Kufareva Chemokines and their receptors: insights from molecular modeling and crystallography. , 2016, Current opinion in pharmacology.

[3]  J. Samra,et al.  Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review , 2016, Oncotarget.

[4]  Hans Clevers,et al.  Modeling Development and Disease with Organoids , 2016, Cell.

[5]  M. Karin,et al.  Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. , 2016, Carcinogenesis.

[6]  D. Cressey Surge in support for animal-research guidelines , 2016, Nature.

[7]  F. Michor,et al.  The mathematics of cancer: integrating quantitative models , 2015, Nature Reviews Cancer.

[8]  D. Lambrechts,et al.  Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma , 2015, Nature Medicine.

[9]  Volker Hovestadt,et al.  Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling , 2015, Nature Communications.

[10]  Francisco J. Sánchez-Rivera,et al.  Applications of the CRISPR–Cas9 system in cancer biology , 2015, Nature Reviews Cancer.

[11]  M. Wunderlich,et al.  Xenograft models for normal and malignant stem cells. , 2015, Blood.

[12]  Neville E. Sanjana,et al.  High-throughput functional genomics using CRISPR–Cas9 , 2015, Nature Reviews Genetics.

[13]  D. Largaespada,et al.  Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery. , 2015, Current opinion in genetics & development.

[14]  Christian Veltkamp,et al.  A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer , 2014, Nature Genetics.

[15]  Kshitij Srivastava,et al.  Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. , 2014, Cancer cell.

[16]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[17]  M. Jong,et al.  Imaging preclinical tumour models: improving translational power , 2014, Nature Reviews Cancer.

[18]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[19]  L. Zon,et al.  Zebrafish cancer: the state of the art and the path forward , 2013, Nature Reviews Cancer.

[20]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[21]  R. Jaenisch,et al.  One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[22]  Tim Holland-Letz,et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.

[23]  Cayetano Gonzalez,et al.  Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics , 2013, Nature Reviews Cancer.

[24]  H. Immervoll,et al.  In vivo animal models for studying brain metastasis: value and limitations , 2013, Clinical & Experimental Metastasis.

[25]  R. Akkina,et al.  New generation humanized mice for virus research: comparative aspects and future prospects. , 2013, Virology.

[26]  L. Nutt The Xenopus oocyte: a model for studying the metabolic regulation of cancer cell death. , 2012, Seminars in cell & developmental biology.

[27]  R. Kerbel,et al.  Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models , 2012, Gut.

[28]  I. Huijbers,et al.  Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

[29]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[30]  R. Kerbel,et al.  Mouse models of advanced spontaneous metastasis for experimental therapeutics , 2011, Nature Reviews Cancer.

[31]  M. Bosenberg,et al.  Mouse melanoma models and cell lines , 2010, Pigment cell & melanoma research.

[32]  M. Ychou,et al.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts , 2010, Nucleic acids research.

[33]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[34]  K. Kiguchi,et al.  Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications , 2009, Nature Protocols.

[35]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[36]  J. Boeke,et al.  Transposon-mediated genome manipulation in vertebrates , 2009, Nature Methods.

[37]  Derek Y. Chiang,et al.  A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma , 2009, Nature Biotechnology.

[38]  Douglas Hanahan,et al.  The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. , 2007, Genes & development.

[39]  Markus F Neurath,et al.  An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression , 2007, Nature Protocols.

[40]  R. Weinberg,et al.  Comparative biology of mouse versus human cells: modelling human cancer in mice , 2003, Nature Reviews Cancer.

[41]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  A. Berns,et al.  Conditional mouse models of sporadic cancer , 2002, Nature Reviews Cancer.

[43]  T. Jacks Tumor suppressor gene mutations in mice. , 1999, Annual review of genetics.

[44]  A. Porter Controlling your losses: conditional gene silencing in mammals. , 1998, Trends in genetics : TIG.

[45]  B. Barrell,et al.  Life with 6000 Genes , 1996, Science.

[46]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.

[47]  S. Cameron,et al.  Cell lineage and cell death: Caenorhabditis elegans and cancer research , 2011, Nature Reviews Cancer.

[48]  Jaap Kool,et al.  High throughput insertional mutagenesis screens in mice to identify oncogenic networks , 2009, Nature Reviews Cancer.

[49]  M. Capecchi The new mouse genetics: altering the genome by gene targeting. , 1989, Trends in genetics : TIG.